Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$3.9B

Dec1Thu

Pre-Earnings Brief

UpcomingQ2-2024After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the health care sector, its work is significant as it aims to address unmet medical needs in oncology, a critical area of research and treatment.

Key Metrics to Watch

EPS

Earnings per share is crucial for assessing the company's profitability and performance relative to expectations.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, resulting in a positive surprise of 44.44%. However, there was no revenue reported against estimates.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as there are no analyst estimates available for this quarter. The market is likely watching closely for any updates on product development and commercialization.

Bull Case

If Legend Biotech can show strong progress in its clinical trials or partnerships, it could lead to positive investor sentiment and a potential stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides negative updates on its pipeline, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of clinical trials for its leading therapies?

Updates on clinical trials are critical as they can significantly impact future revenue and investor confidence.

Will there be any guidance on revenue expectations for the upcoming quarters?

Guidance on revenue can set market expectations and influence stock performance in the near term.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive clinical trial results, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility which may not align with current consensus.

The company's recent EPS surprise indicates a trend of outperforming expectations, suggesting potential for continued positive surprises.

Key Risk

If clinical trial results exceed expectations, it could shift the market's perception significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to deliver on its clinical pipeline and provide revenue guidance.

Bull Confirmed If

A clear update on successful clinical trial results could validate the bull case and lead to a stock price increase.

Bear Confirmed If

Any indication of delays or failures in clinical trials could confirm the bear case and lead to a stock price decline.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71% on the first day.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential drop of around 6.91% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Any guidance on expected revenue for the next quarter.
3Insights into partnerships or collaborations that may impact growth.
4Management's outlook on market conditions and competitive landscape.
5Details on any regulatory updates or approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is crucial for assessing the company's profitability and performance relative to expectations.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as there are no analyst estimates available for this quarter. The market is likely watching closely for any updates on product development and commercialization.

Bull Case

If Legend Biotech can show strong progress in its clinical trials or partnerships, it could lead to positive investor sentiment and a potential stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides negative updates on its pipeline, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of clinical trials for its leading therapies?

Updates on clinical trials are critical as they can significantly impact future revenue and investor confidence.

Will there be any guidance on revenue expectations for the upcoming quarters?

Guidance on revenue can set market expectations and influence stock performance in the near term.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive clinical trial results, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility which may not align with current consensus.

The company's recent EPS surprise indicates a trend of outperforming expectations, suggesting potential for continued positive surprises.

Key Risk

If clinical trial results exceed expectations, it could shift the market's perception significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to deliver on its clinical pipeline and provide revenue guidance.

Bull Confirmed If

A clear update on successful clinical trial results could validate the bull case and lead to a stock price increase.

Bear Confirmed If

Any indication of delays or failures in clinical trials could confirm the bear case and lead to a stock price decline.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71% on the first day.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential drop of around 6.91% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Any guidance on expected revenue for the next quarter.
3Insights into partnerships or collaborations that may impact growth.
4Management's outlook on market conditions and competitive landscape.
5Details on any regulatory updates or approvals.